Skip to content
MARKETS / NASDAQ / VTRS
NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Viatris Inc. VTRS

8 fiscal years on record · USD · FY2025 reported · SEC filings only
$14.3B
▼ 3.0% YoY
$-3.5B
$1.9B
▼ 2.0% YoY
In brief

What this company does

Viatris supplies medicines to approximately 1 billion patients around the world each year. The company operates in more than 165 countries and territories with more than 30,000 employees. Viatris has four reportable segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in mainland China, Taiwan, and Hong Kong. The JANZ segment consists of its operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies across Asia, Africa, Eastern Europe, Latin America and the Middle East, as well as the company's ARV franchise.

Written from the business description in Viatris Inc's annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth
USD 14.3B
Revenue, FY2025 · full 8-year series below
Revenue $B Net income $B
FY2025 · Revenue 14.3 · Net income -3.5
8B16B-2B20182019202020212022202320242025
Compound annual growth
−4.2%
+3.6%
+0.0%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +3.6% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−25 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -18.7% · Net -24.7%
5%10%-10%-20%20182019202020212022202320242025
ROE

No chart to show — the reason differs by year; see each year in the table below.

Cash & shareholders
USD 497.9M
returned in FY2025 · dividends + net buybacks
Free cash flow $B
FY2025 · FCF 1.9
1B2B20182019202020212022202320242025
Net buybacks $M Dividends $M
FY2025 · Dividends — · Net buybacks 497.9
200M400M20182019202020212022202320242025

USD 497.9M in buybacks went back to shareholders.

Total assetsUSD 37.2B
CashUSD 1.3B
Gross debtUSD 14.4B
Net debtUSD 13.1B
Current ratio1.38×

Not available: we don't have the shareholders' equity figure for this period.

The 8-year record
8 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018
Revenue $B14.314.715.416.217.911.911.511.4
Operating income $B−2.70.00.81.6−0.0−0.20.70.9
EBITDA $B0.12.93.54.64.52.02.73.0
Income tax $B−0.20.00.10.70.6−0.10.1−0.1
Net income $B−3.5−0.60.12.1−1.3−0.70.00.4
Free cash flow $B1.92.02.52.62.61.01.62.1
EPS, diluted $−3.00−0.530.051.71−1.05−1.110.030.68
Dividend / sh $0.480.480.480.480.33···
Payout %········
ROE %········
Shares out B······0.00·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 37 reconciliationsAUDITED

Reconciled in 9 of 19 fiscal years. 58 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2017

Share this section

Download image